Search
for
Sort by
Research 15
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
- Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
- Evolving CRBN ligands enhance the drug-like properties of protein degraders
- Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
- Autoimmune Polyglandular Syndrome Type 1 in Russian Patients: Clinical Variants and Autoimmune Regulator Mutations
- PROTACs: A novel strategy for cancer drug discovery and development
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Emerging Strategies in Smart Nano-PROTAC for Stimuli-Responsive Protein Degradation and Precision Cancer Therapy
- Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
- Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation
- Protein degradation: expanding the toolbox to restrain cancer drug resistance
- Advancing Design Strategy of PROTACs for Cancer Therapy
- Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems
- PROTACs in 2025: from the laboratory concept to clinical breakthrough
- Adsorption of Diclofenac and PFBS on a Hair Keratin Dimer